SETTLEMENT AGREEMENT

This Settlement Agreement ("Agreement") is entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General (OIG-HHS) of the Department of Health and Human Services (HHS) (collectively, the “United States”), and Pfizer, Inc. (hereafter collectively referred to as “the Parties”), through their authorized representatives.

RECITALS

A. Pfizer, Inc. (“Pfizer”) is a Delaware corporation with principal executive offices located in New York, New York. Pfizer manufacturers and markets pharmaceutical products in the United States, including Sutent and Inlyta, both of which are indicated to treat renal cell carcinoma, and Tikosyn, which is indicated to treat arrhythmia in patients with atrial fibrillation or atrial flutter (collectively the “Subject Drugs”).

B. The United States contends that Pfizer caused to be submitted claims for payment for the Subject Drugs to the Medicare Program, Title XVIII of the Social Security Act, 42 U.S.C. § 1395-1395lll (“Medicare”).

C. When a Medicare beneficiary obtains a prescription drug covered by Medicare Part B or Part D, the beneficiary may be required to make a payment, which may take the form of a “copayment,” “coinsurance,” or “deductible” (collectively “copays”). The Anti-Kickback Statute, 42 U.S.C. § 1320a-7b, prohibits pharmaceutical companies from paying remuneration to induce Medicare beneficiaries to purchase, or their physicians to prescribe, drugs that are reimbursed by Medicare.

D. The Patient Access Network Foundation (“PANF”), an entity claiming 501(c)(3) status for tax purposes, operates funds that pay the copays of certain patients, including Medicare patients.
E. The United States contends that it has certain civil claims, as specified in Paragraph 2 below, against Pfizer for engaging in the conduct below during the period from January 1, 2012, through December 31, 2016 (hereinafter referred to as the “Covered Conduct”). Specifically, the United States alleges:

Pfizer made donations to PANF and used PANF as a conduit to pay the copay obligations of Medicare patients taking the Subject Drugs. With respect to Sutent and Inlyta, Pfizer contracted with Advanced Care Scripts (“ACS”) to act as a third-party specialty pharmacy for Sutent and Inlyta patients prescribed those products, including Medicare patients. In order to generate revenue and instead of giving away Sutent and Inlyta for free to Medicare patients who met the financial qualifications of Pfizer’s existing free drug program, Pfizer worked with ACS to transition some portion of these patients to PANF, which covered the patients’ Medicare copays and caused Medicare claims to result from the filling of the patients’ Sutent and Inlyta prescriptions. In connection with this initiative, Pfizer made donations to PANF and thereafter received data from PANF, via ACS, confirming that PANF funded the Medicare copays of Sutent and Inlyta patients. With respect to Tikosyn, Pfizer raised the wholesale acquisition cost of a package of 40 .125 mg capsules of the drug from $220.24 to $317.15 in the last three months of 2015. Knowing the price increase would increase Medicare beneficiaries’ copay obligations for Tikosyn, which could result in more Medicare patients needing financial assistance to fill their Tikosyn prescriptions, Pfizer worked with PANF to create and finance a fund for Medicare patients being treated for arrhythmia with atrial fibrillation or atrial flutter. Pfizer coordinated the timing of the opening of PANF’s fund for these patients with the implementation of a Tikosyn price increase, and Pfizer then began referring to PANF any Medicare patients who needed financial assistance to meet their newly-increased copays for the drug. For the next nine
months, Tikosyn patients accounted for virtually all of the beneficiaries of PANF’s fund for Medicare patients being treated for arrhythmia with atrial fibrillation or atrial flutter.

F. In consideration of the mutual promises and obligations of this Settlement Agreement, the Parties agree and covenant as follows:

TERMS AND CONDITIONS

1. Pfizer shall pay to the United States twenty three million eighty hundred fifty thousand dollars ($23,850,000), plus interest at a rate of 5.00% from January 1, 2018, through the day before full payment (the “Settlement Amount”) no later than ten days after the Effective Date of this Agreement by electronic funds transfer pursuant to written instructions to be provided by the Office of the United States Attorney for District of Massachusetts. Of the Settlement Amount, $13,250,000 is restitution to the United States.

2. Subject to the exceptions in Paragraph 4 (concerning excluded claims) below, and conditioned upon Pfizer’s full payment of the Settlement Amount, the United States releases Pfizer, together with its predecessors, and its current and former divisions, parents, subsidiaries, successors and assigns, from any civil or administrative monetary claim the United States has for the Covered Conduct under the False Claims Act, 31 U.S.C. §§ 3729-33, the Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a, the Program Fraud Civil Remedies Act, 31 U.S.C. §§ 3801-12, or the common law theories of payment by mistake, unjust enrichment, and fraud.

3. In consideration of the obligations of Pfizer in this Agreement and the Corporate Integrity Agreement (“CIA”) entered into between OIG-HHS and Pfizer, and conditioned upon Pfizer’s full payment of the Settlement Amount, the OIG-HHS agrees to release and refrain from instituting, directing, or maintaining any administrative action seeking exclusion from Medicare, Medicaid, and other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) against Pfizer under 42 U.S.C. § 1320a-7a (Civil Monetary Penalties Law) or 42 U.S.C. § 1320a-7(b)(7)
(permissive exclusion for fraud, kickbacks, and other prohibited activities) for the Covered Conduct, except as reserved in this Paragraph and in Paragraph 4 (concerning excluded claims), below. The OIG-HHS expressly reserves all rights to comply with any statutory obligations to exclude Pfizer from Medicare, Medicaid, and other Federal health care programs under 42 U.S.C. § 1320a-7(a) (mandatory exclusion) based upon the Covered Conduct. Nothing in this Paragraph precludes the OIG-HHS from taking action against entities or persons, or for conduct and practices, for which claims have been reserved in Paragraph 4, below.

4. Notwithstanding the releases given in paragraphs 2 and 3 of this Agreement, or any other term of this Agreement, the following claims of the United States are specifically reserved and are not released:

   a. Any liability arising under Title 26, U.S. Code (Internal Revenue Code);

   b. Any criminal liability;

   c. Except as explicitly stated in this Agreement, any administrative liability, including mandatory exclusion from Federal health care programs;

   d. Any liability to the United States (or its agencies) for any conduct other than the Covered Conduct;

   e. Any liability based upon obligations created by this Agreement;

   f. Any liability of individuals;

   g. Any liability for express or implied warranty claims or other claims for defective or deficient products or services, including quality of goods and services;

   h. Any liability for failure to deliver goods or services due;

   i. Any liability for personal injury or property damage or for other consequential damages arising from the Covered Conduct;
5. Pfizer waives and shall not assert any defenses Pfizer may have to any criminal prosecution or administrative action relating to the Covered Conduct that may be based in whole or in part on a contention that, under the Double Jeopardy Clause in the Fifth Amendment of the Constitution, or under the Excessive Fines Clause in the Eighth Amendment of the Constitution, this Agreement bars a remedy sought in such criminal prosecution or administrative action.

6. Pfizer fully and finally releases the United States, its agencies, officers, agents, employees, and servants, from any claims (including attorney’s fees, costs, and expenses of every kind and however denominated) that Pfizer has asserted, could have asserted, or may assert in the future against the United States, and its agencies, officers, agents, employees, and servants related to the Covered Conduct and the United States’ investigation and prosecution thereof.

7. The Settlement Amount shall not be decreased as a result of the denial of claims for payment now being withheld from payment by any Medicare contractor (e.g., Medicare Administrative Contractor, fiscal intermediary, carrier) or any state payer, related to the Covered Conduct; and Pfizer agrees not to resubmit to any Medicare contractor or any state payer any previously denied claims related to the Covered Conduct, agrees not to appeal any such denials of claims, and agrees to withdraw any such pending appeals.

8. Pfizer agrees to the following:
   a. **Unallowable Costs Defined:** All costs (as defined in the Federal Acquisition Regulation, 48 C.F.R. § 31.205-47; and in Titles XVIII and XIX of the Social Security Act, 42 U.S.C. §§ 1395-1395kkk-1 and 1396-1396w-5; and the regulations and official program directives promulgated thereunder) incurred by or on behalf of Pfizer, its present or former officers, directors, employees, shareholders, and agents in connection with:
      (1) the matters covered by this Agreement;
(2) the United States’ audit(s), and any civil or criminal investigations of the
matters covered by this Agreement;

(3) Pfizer’s investigation, defense, and corrective actions undertaken in
response to the United States’ audit(s) and any civil or criminal
investigation(s) in connection with the matters covered by this Agreement
(including attorney’s fees);

(4) the negotiation and performance of this Agreement;

(5) the payment Pfizer makes to the United States pursuant to this Agreement;

and

(6) the negotiation of, and obligations undertaken pursuant to the CIA to: (i)
retain an independent review organization to perform annual reviews as
described in Section III of the CIA; and (ii) prepare and submit reports to
the OIG-HHS,

are unallowable costs for government contracting purposes and under the Medicare Program,
Medicaid Program, TRICARE Program, and Federal Employees Health Benefits Program
(“FEHBP”) (hereinafter referred to as Unallowable Costs). However, nothing in paragraph
8.a.(6) that may apply to the obligations undertaken pursuant to the CIA affects the status of
costs that are not allowable based on any other authority applicable to Pfizer.

b. Future Treatment of Unallowable Costs: Unallowable Costs shall be
separately determined and accounted for by Pfizer, and Pfizer shall not charge such Unallowable
Costs directly or indirectly to any contracts with the United States or any State Medicaid
program, or seek payment for such Unallowable Costs through any cost report, cost statement,
information statement, or payment request submitted by Pfizer or any of its subsidiaries or
affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.
c. Treatment of Unallowable Costs Previously Submitted for Payment:
Pfizer further agrees that, within 90 days of the Effective Date of this Agreement, it shall identify
to applicable Medicare and TRICARE fiscal intermediaries, carriers, and/or contractors, and
Medicaid and FEHBP fiscal agents, any Unallowable Costs (as defined in this Paragraph)
included in payments previously sought from the United States, or any State Medicaid program,
including, but not limited to, payments sought in any cost reports, cost statements, information
reports, or payment requests already submitted by Pfizer or any of its subsidiaries or affiliates,
and shall request, and agree, that such cost reports, cost statements, information reports, or
payment requests, even if already settled, be adjusted to account for the effect of the inclusion of
the unallowable costs. Pfizer agrees that the United States, at a minimum, shall be entitled to
recoup from Pfizer any overpayment plus applicable interest and penalties as a result of the
inclusion of such Unallowable Costs on previously-submitted cost reports, information reports,
cost statements, or requests for payment.

Any payments due after the adjustments have been made shall be paid to the United
States pursuant to the direction of the Department of Justice and/or the affected agencies. The
United States reserves its rights to disagree with any calculations submitted by Pfizer or any of
its subsidiaries or affiliates on the effect of inclusion of Unallowable Costs (as defined in this
Paragraph) on Pfizer or any of its subsidiaries or affiliates’ cost reports, cost statements, or
information reports.

d. Nothing in this Agreement shall constitute a waiver of the rights of the
United States to audit, examine, or re-examine Pfizer books and records to determine that no
Unallowable Costs have been claimed in accordance with the provisions of this Paragraph.
9. This Agreement is intended to be for the benefit of the Parties only. The Parties do not release any claims against any other person or entity, except to the extent provided for in Paragraph 10 (waiver for beneficiaries paragraph), below.

10. Pfizer agrees that it waives and shall not seek payment for any of the health care billings covered by this Agreement from any health care beneficiaries or their parents, sponsors, legally responsible individuals, or third party payors based upon the claims defined as Covered Conduct.

11. Each Party shall bear its own legal and other costs incurred in connection with this matter, including the preparation and performance of this Agreement.

12. Each party and signatory to this Agreement represents that it freely and voluntarily enters into this Agreement without any degree of duress or compulsion.

13. This Agreement is governed by the laws of the United States. The exclusive jurisdiction and venue for any dispute relating to this Agreement is the United States District Court for the District of Massachusetts. For purposes of construing this Agreement, this Agreement shall be deemed to have been drafted by all Parties to this Agreement and shall not, therefore, be construed against any Party for that reason in any subsequent dispute.

14. This Agreement constitutes the complete agreement between the Parties. This Agreement may not be amended except by written consent of the Parties.

15. The undersigned counsel represent and warrant that they are fully authorized to execute this Agreement on behalf of the persons and entities indicated below.

16. This Agreement may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same Agreement.

17. This Agreement is binding on Pfizer’s successors, transferees, heirs, and assigns.
18. All parties consent to the United States’ disclosure of this Agreement, and information about this Agreement, to the public.

19. This Agreement is effective on the date of signature of the last signatory to the Agreement (Effective Date of this Agreement). Facsimiles and electronic transmissions of signatures shall constitute acceptable, binding signatures for purposes of this Agreement.
THE UNITED STATES OF AMERICA

DATED: 5/12/18

BY:

GREGG SHERIRO
ABRAHAM GEORGE
DEANA EL-MALLAWANY
Assistant United States Attorneys
United States Attorney's Office
District of Massachusetts

DATED: 5/23/18

BY:

SARAH ARNI
Attorneys
Commercial Litigation Branch
Civil Division
United States Department of Justice

DATED: 5/23/18

BY:

Assistant Inspector General for Legal Affairs
Office of Counsel to the Inspector General
Office of Inspector General
United States Department of Health and Human Services

PFIZER, INC.

DATED: May 20, 2018

BY:

CARLTON WESSEL
Senior Vice President, Associate General Counsel

DATED: May 21, 2018

BY:

LAURA HOEY
Ropes & Gray LLP
Counsel for Pfizer, Inc.